Molnupiravir

Summarized by Plex Health
Last Updated: 03 May 2022

Molnupiravir is a speculative medicine being researched for the therapy of mild-to-moderate COVID-19. The United States Food and Drug Administration has accredited emergency situation use of molnupiravir for the treatment of mild-to-moderate COVID-19 in people 18 years old and older. Your name may be noted on a maternity registry to track the effects of molnupiravir on the baby if you are pregnant. For investigational use only 800 mg by mouth every 12 hrs for 5 days Comments: -The U.S. FDA issued an Emergency Use Authorization to permit the emergency use of the unauthorized medication molnupiravir for the treatment of mild to modest coronavirus disease 2019 in patients with positive outcomes of straight serious acute respiratory syndrome coronavirus 2 viral testing, AND who are at high risk for development to severe COVID-19, consisting of a hospital stay or fatality, AND for whom alternate COVID-19 therapy options authorized by United States FDA are not accessible/clinically suitable; this drug is not accepted by the U.S. FDA for this use. Molnupiravir is only readily available on prescription. Nevertheless, you will only be qualified to have the medication either: if you're in the high risk group; through a national research study where half of participants will be offered the medicine. , if you are in the high risk group you might be sent out and pcr and a letter test that you can as well as at home should you develop symptoms of COVID-19. You'll require to begin taking the pills as soon as possible after you have tested positive for COVID-19 and within 5 days of your symptoms starting. You will take 4 molnupiravir pills twice a day for 5 days. Common side effects of molnupiravir include feeling lightheaded and headaches. ; March 7, 2022: New "Test to Treat Initiative" Makes COVID Treatments More Accessible to Those Who Need Them Most; December 23, 2021: FDA Authorizes Additional Oral Antiviral, Lagevrio, for Treatment of COVID-19 in Certain Adults. The U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response will oversee the equitable and fair allocation of Lagevrio to state and territorial health and wellness divisions and, choose Health Resources and Services Administration -funded health centers. Wellness departments will have understanding into picked HRSA-funded university hospital and their product appropriations and coverage.

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.

PubChem - CovalentUnitCount

(Table source)
CIDMolecularFormulaMolecularWeightCanonicalSMILESIsomericSMILESInChIInChIKeyIUPACNameXLogPExactMassMonoisotopicMassTPSAComplexityChargeHBondDonorCountHBondAcceptorCountRotatableBondCountHeavyAtomCountIsotopeAtomCountAtomStereoCountDefinedAtomStereoCountUndefinedAtomStereoCountBondStereoCountDefinedBondStereoCountUndefinedBondStereoCountCovalentUnitCount
145996610C13H19N3O7329.31CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)NO)O)OCC(C)C(=O)OC[[email protected]@H]1[[email protected]]([[email protected]]([[email protected]@H](O1)N2C=CC(=NC2=O)NO)O)OInChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1HTNPEHXGEKVIHG-QCNRFFRDSA-N[(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate-0.8329.12229995329.1222999514153404762304400001
*** If you want us to remove all links leading to your domain from Plex.page and never use your website as a source of the "Online Knowledge", please contact us using a corporate email and we will remove everything in 10 business days.

logo

Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.